Name and address of the site: phi Pharma International GmbH & Co. KG
(ORG-100038309 / LOC-100060282)
, Carl-Zeiss-Strasse 31, Hechtsheim, Mainz, Rhineland-Palatinate, 55129, Germany
Human medicinal products
1. MEDICINAL PRODUCTS
1.1. with a Marketing Authorisation or registration in EEA country(s)
1.2. without a Marketing Authorisation or registration in the EEA and intended for EEA market*
1.3. without a Marketing Authorisation or registration in the EEA and intended for exportation
|
2. AUTHORISED WHOLESALE DISTRIBUTION OPERATIONS
2.1. Procurement
2.2. Holding
2.3. Supply
2.4. Export
2.5. Other activities(s): (please specify) Activities within the scope of Sect 73 para 2, no. 2, 2a, 3, 3a AMG and Sect 73 para 3 AMG |Tätigkeiten im Rahmen des § 73 Abs. 2 Nr. 2, 2a, 3, 3a AMG und § 73 Abs. 3 AMG
|
3. MEDICINAL PRODUCTS WITH ADDITIONAL REQUIREMENTS
3.1. Narcotic or psychotropic products**
3.2. Products requiring low temperature handling
3.2.1. Temperatures between 2 to 8 °C
3.3. Other products: (please specify here or make a reference to Annex 5) Medicinal products derived from blood; immunological medicinal prod. acc. to Art. 83 of 2001/83/EC | Arzneimittel aus Blut, immunologische Arzneimittel entsprechend Art. 83 der Richtlinie 2001/83/EC
|
Any restrictions or clarifying remarks (for all users): Archiving is also performed in the 2th upper floor within the building Carl-Zeiss-Strasse 26, 55129 Mainz. To 3.1.: Wholesale activities cover also the wholesale with the following products: Cannabis Flos, standardized Cannabis Extract and finished medicinal products, which are covered by MedCanG. ---
Die Archivierung erfolgt zusätzlich in den Räumlichkeiten im 2. Obergeschoss der Carl-Zeiss-Straße 26, 55129 Mainz. Zu Punkt 3.1.: Die Großhandelstätigkeit umfasst auch den Handel mit folgenden Produkten: Cannabis Flos, eingestellter Cannabisextrakt und Fertigarzneimittel, die unter das MedCanG fallen.
*Art. 5 of Directive 2001/83/EC, Art. 83 of Regulation (EC) 726/2004 and Art. 110 of Regulation 2019/6.
**Without prejudice to further authorisations as may be required according to national legislation.
|